Literature DB >> 20136724

Contribution of B7RP-1/ICOS co-stimulation to lethal acute GVHD.

Junya Fujimura1, Kazuyoshi Takeda, Yuki Kaduka, Masahoro Saito, Hisaya Akiba, Hideo Yagita, Yuichiro Yamashiro, Toshiaki Shimizu, Ko Okumura.   

Abstract

Co-stimulatory molecules expressed on T cells critically regulate donor T-cell activation and are implicated in acute GVHD after allogeneic BMT. We here investigated the role of interaction between B7-related protein-1 (B7RP-1) and ICOS in murine acute GVHD model that received T cell-depleted BM cells and splenocytes. Administration of blocking anti-B7RP-1 mAb significantly reduced the lethality and symptoms in acute GVHD. A significant hypo-responsiveness of splenocytes to host alloantigen was observed in the recipient mice treated with anti-B7RP-1 mAb. Moreover, acute GVHD was significantly reduced in the recipients of T cells composed of ICOS-deficient CD8 T cells and WT CD4 T cells compared with that in the recipients of T cells composed of WT CD8 T cells and ICOS-deficient CD4 T cells. These results suggested that B7RP-1/ICOS co-stimulatory signal plays a role in the activation of alloantigen-reactive donor T cells, particularly in CD8 T cells, in murine acute GVHD model, and that the blockade of B7RP-1/ICOS interaction may be useful for selectively manipulating allo-reactive T cells in the recipients with acute GVHD. Copyright (c) 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20136724     DOI: 10.1111/j.1399-3046.2009.01279.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  7 in total

1.  Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Authors:  Mohammad S Hossain; David L Jaye; Brian P Pollack; Alton B Farris; Malefa L Tselanyane; Ebenezer David; John D Roback; Andrew T Gewirtz; Edmund K Waller
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

2.  Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease.

Authors:  Scott S Graves; Maura H Parker; Diane Stone; George E Sale; Smitha P S Pillai; Melissa M Johnson; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-25       Impact factor: 5.742

Review 3.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

4.  A Canine Model of Chronic Graft-versus-Host Disease.

Authors:  Scott S Graves; Andrew Rezvani; George Sale; Diane Stone; Maura Parker; Steven Rosinski; Michele Spector; Bruce Swearingen; Leslie Kean; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

5.  Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.

Authors:  Masahiko Sato; Rainer Storb; Carol Loretz; Diane Stone; Marco Mielcarek; George E Sale; Andrew R Rezvani; Scott S Graves
Journal:  Transplantation       Date:  2013-07-15       Impact factor: 4.939

6.  Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease.

Authors:  Ruishu Deng; Christian Hurtz; Qingxiao Song; Chanyu Yue; Gang Xiao; Hua Yu; Xiwei Wu; Markus Muschen; Stephen Forman; Paul J Martin; Defu Zeng
Journal:  Nat Commun       Date:  2017-10-17       Impact factor: 14.919

Review 7.  The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.

Authors:  Sandeep Kumar; Nicholas D Leigh; Xuefang Cao
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.